Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Vascular Biogenics Ltd. (VBLT) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/09/2022 6-K Quarterly results
11/14/2022 6-K Quarterly results
09/01/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-36581 Vascular Biogenics Ltd. 8 HaSatat St., Modi’ in, Israel 7178106 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ On August 31, 2022, Vascular Biogenics Ltd. received a deficiency letter fro...",
"VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency"
08/15/2022 6-K Quarterly results
08/02/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-36581 Vascular Biogenics Ltd. 8 HaSatat St., Modi’ in, Israel 7178106",
"VBL Therapeutics Announces Workforce Reduction"
07/19/2022 6-K Quarterly results
07/08/2022 6-K Quarterly results
06/02/2022 6-K Quarterly results
05/17/2022 6-K Quarterly results
04/26/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2022 Commission File Number: 001-36581 Vascular Biogenics Ltd. 8 HaSatat St., Modi’ in, Israel 7178106 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ On April 26, 2022, Vascular Biogenics Ltd. issued a press release announcing that t...",
"VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer"
03/23/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2022 Commission File Number: 001-36581 Vascular Biogenics Ltd. 8 HaSatat St., Modi’ in, Israel 7178106 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ On March 23, 2022, Vascular Biogenics Ltd. issued the following press release annou...",
"VASCULAR BIOGENICS LTD. CONSOLIDATED BALANCE SHEETS December 31 2021 2020 U.S. dollars in thousands ASSETS Current assets: Cash and cash equivalents $ 21,986 $ 13,184 Restricted bank deposits - 151 Short-term bank deposits 31,164 17,110 Trade receivables - 129 Other current assets 1,697 1,419 Total current assets 54,847 31,993 Non-current assets: Restricted bank deposits $ 362 362 Long-term prepaid expenses 182 241 Funds in respect of employee rights upon retirement 415 354 Property, plant and equipment, net 6,847 6,632 Operating lease right-of-use assets 2,008 2,124 Total non-current assets 9,814 9,713 Total assets $ 64,661 $ 41,706 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable: Trade $ 4,331 $ 1,960 Other 4,408 4,275 Deferred revenue 658 725 Current maturity ..."
03/08/2022 6-K Quarterly results
02/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Inducement Plan (2022)",
"Inducement Plan (2022)"
02/11/2022 6-K Quarterly results
12/20/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2021 Commission File Number: 001-36581 Vascular Biogenics Ltd. 8 HaSatat St Modi’ in Israel 7178106 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ On December 20, 2021, Vascular Biogenics Ltd. issued a press release announcing its...",
"VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program"
11/15/2021 6-K Quarterly results
Docs: "Exhibits Exhibit No. Description",
"VBL Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update",
"CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION",
"OPERATING AND FINANCIAL REVIEW AND PROSPECTS"
10/20/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2021 Commission File Number: 001-36581 Vascular Biogenics Ltd. 8 HaSatat St., Modi’ in, Israel 7178106 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ EXPLANATORY NOTE As previously disclosed, on October 19, 2021, Vascular Biogenics..."
10/05/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2021 Commission File Number: 001-36581 Vascular Biogenics Ltd. 8 HaSatat St., Modi’ in, Israel 7178106 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ On October 5, 2021, Vascular Biogenics Ltd. issued the following press release an...",
"VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States"
09/17/2021 6-K Quarterly results
09/02/2021 6-K Quarterly results
08/30/2021 6-K Quarterly results
08/16/2021 6-K Quarterly results
07/08/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2021 Commission File Number: 001-36581 Vascular Biogenics Ltd. 8 HaSatat St., Modi’ in, Israel 7178106 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: [ ] On July 8, 2021, Vascular Biogenics Ltd. issued the following press release announcing the appointme...",
"VBL Therapeutics Appoints Alison Finger and Michael Rice to"
06/15/2021 6-K Quarterly results
06/04/2021 6-K Quarterly results
05/11/2021 6-K Quarterly results
04/12/2021 6-K Quarterly results
04/06/2021 6-K Quarterly results
01/15/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2021 Commission File Number: 001-36581 Vascular Biogenics Ltd. 8 HaSatat St., Modi’ in, Israel 7178106 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: Yes [ ] No [X] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: Yes [ ] No [X] Indicate by check mark whether by furnishing the information contained in t...",
"Opinion of Horn & Co., counsel to the registrant",
"Ordinary Shares Purchase Agreement, between Vascular Biogenics Ltd. and Aspire Capital Fund, LLC",
"Registration Rights Agreement, between Intec Pharma Ltd. and Aspire Capital Fund, LLC",
"Press Release"
11/16/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2020 Commission File Number: 001-36581 Vascular Biogenics Ltd. 8 HaSatat St Modi’ in Israel 7178106 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: [ ] Indicate by check mark whether by furnishing the information contained in this Form, the registrant..."
10/29/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2020 Commission File Number: 001-36581 Vascular Biogenics Ltd. 8 HaSatat St., Modi’ in, Israel 7178106 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: Yes [ ] No [X] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: Yes [ ] No [X] Indicate by check mark whether by furnishing the information contained in t..."
10/19/2020 6-K Quarterly results
10/13/2020 6-K Quarterly results
08/13/2020 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy